semaglutide alzheimer's clinical trial Details of failed studies cast pall on Novo Nordisk's GLP-1 as treatment Blockbuster GLP-1 Diabetes and Weight

Originally developed for type 2 diabetes, semaglutide has gained significant recognition for its powerful effectiveness in promoting safe and sustainable weight loss

RA is a chronic illness, which means treatment often continues for life

In more extreme cases, it can cause significant nutritional deficiencies and a reduction in body weight as it struggles to absorb and process nutrients efficiently

We typically use or share your health information in the following ways

Heres what you need to know: Patent Expiration and Generic Applications: Novo Nordisks regulatory exclusivity for semaglutide expired on January 4, 2026, clearing the path for generic manufacturers